Psilocybin Therapy for Treatment-Resistant Depression Shows Promise as FDA Approval Is Considered
Summary
Psilocybin therapy may become an option for treatment-resistant depression, with Compass Pathways reporting two positive Phase 3 trials of its COMP360 formulation. A separate 2026 study found lower depression scores with COMP360 than with placebo, while a 2022 study suggested benefits alongside psychotherapy could last a year. Researchers are investigating effects on brain plasticity and circuits involved in self-perception, but trials are difficult to blind because participants can often tell whether they received a psychedelic. If approved, treatment would likely occur under clinical supervision. Risks include anxiety, elevated blood pressure and possible psychosis in susceptible people, making medical and psychiatric screening important. Approval is not guaranteed.